AATec Medical GmbH (AATec), a biotech company developing a multi-product platform to treat respiratory diseases, and Northway Biotech (NBT), a global CDMO, partnered for manufacturing process development and analytical development of AATec’s lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).

Per the agreement, NBT will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system.

ATL-105 was developed to treat NCFB, a chronic inflammatory respiratory condition. This disease is marked by dilated bronchi, persistent inflammation, frequent airway infections, and impaired mucus clearance. 

In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, including COPD, ARDS, and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.

Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, said, ”ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and anti-infective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis.”